Evolus Announces Board Changes and Director Elections

An announcement from Evolus ( (EOLS) ) is now available.

On June 5, 2025, Evolus, Inc. experienced significant changes in its board of directors as part of a planned transition, with Simone Blank stepping down and Albert White III joining the Audit Committee. Additionally, during the Annual Meeting of Stockholders, David Gill and Albert White III were elected as Class I Directors, Ernst & Young LLP was ratified as the independent accounting firm, and the compensation of the company’s executive officers was approved.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Spark’s Take on EOLS Stock

According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.

Evolus’ overall score reflects strong revenue growth and strategic initiatives, such as securing a new credit facility, which are positive factors. However, the company’s ongoing financial instability, bearish technical indicators, and unattractive valuation considerably weigh down the score.

To see Spark’s full report on EOLS stock, click here.

More about Evolus

Evolus, Inc. operates in the medical aesthetics industry, focusing on providing innovative products and services to enhance aesthetic outcomes for patients.

Average Trading Volume: 989,047

Technical Sentiment Signal: Sell

Current Market Cap: $631.9M

See more insights into EOLS stock on TipRanks’ Stock Analysis page.